menu

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Drug Info Rounds

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

close
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
RestartResume
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/21/20